BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34847284)

  • 21. Molecular alterations in Hürthle cell neoplasms of thyroid: A fine needle aspiration cytology study with cytology-histology correlation.
    Gilani SM; Ross JA; Prasad ML; Hammers L; Cai G; Adeniran AJ
    Cancer Cytopathol; 2021 May; 129(5):363-373. PubMed ID: 33045146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of different methodologies on the detection of point mutations in routine air-dried fine needle aspiration (FNA) smears.
    Rehfeld C; Münz S; Krogdahl A; Jensen EM; Siebolts U; Ferraz C; Bösenberg E; Hegedüs L; Paschke R; Eszlinger M
    Horm Metab Res; 2013 Jul; 45(7):513-7. PubMed ID: 23508716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative detection of RAS mutation may guide extent of thyroidectomy.
    Patel SG; Carty SE; McCoy KL; Ohori NP; LeBeau SO; Seethala RR; Nikiforova MN; Nikiforov YE; Yip L
    Surgery; 2017 Jan; 161(1):168-175. PubMed ID: 27863786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular genotyping of follicular variant of papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testing.
    Lee SR; Jung CK; Kim TE; Bae JS; Jung SL; Choi YJ; Kang CS
    Thyroid; 2013 Nov; 23(11):1416-22. PubMed ID: 23590130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular analysis of residual ThinPrep material from thyroid FNAs increases diagnostic sensitivity.
    Krane JF; Cibas ES; Alexander EK; Paschke R; Eszlinger M
    Cancer Cytopathol; 2015 Jun; 123(6):356-61. PubMed ID: 25926393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF and RAS mutations in follicular variants of papillary thyroid carcinoma.
    Park JY; Kim WY; Hwang TS; Lee SS; Kim H; Han HS; Lim SD; Kim WS; Yoo YB; Park KS
    Endocr Pathol; 2013 Jun; 24(2):69-76. PubMed ID: 23625203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative detection of malignancy in fine-needle aspiration cytology (FNAC) smears with indeterminate cytology (Bethesda III, IV) by a combined molecular classifier.
    Titov S; Demenkov PS; Lukyanov SA; Sergiyko SV; Katanyan GA; Veryaskina YA; Ivanov MK
    J Clin Pathol; 2020 Nov; 73(11):722-727. PubMed ID: 32213552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of a Multigene Genomic Classifier in Thyroid Nodules with Suspicious for Malignancy Cytology.
    Skaugen JM; Taneja C; Liu JB; Wald AI; Nikitski AV; Chiosea SI; Seethala RR; Ohori NP; Karslioglu-French E; Carty SE; Nikiforova MN; Yip L; Nikiforov YE
    Thyroid; 2022 Dec; 32(12):1500-1508. PubMed ID: 35864811
    [No Abstract]   [Full Text] [Related]  

  • 29. Thyroid cytology smear slides: An untapped resource for ThyroSeq testing.
    Nikiforova MN; Lepe M; Tolino LA; Miller ME; Ohori NP; Wald AI; Landau MS; Kaya C; Malapelle U; Bellevicine C; Troncone G; Nikiforov YE; Baloch Z
    Cancer Cytopathol; 2021 Jan; 129(1):33-42. PubMed ID: 32697051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytological features and nuclear scores: Diagnostic tools in preoperative fine needle aspiration of indeterminate thyroid nodules with RAS or BRAF K601E mutations?
    Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
    Cytopathology; 2021 Jan; 32(1):37-44. PubMed ID: 32803788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Probability of malignancy and molecular alterations as determined by ThyroSeq v3 genomic classifier in Bethesda Category IV.
    Tjendra Y; Kerr DA; Zuo Y; Menendez SG; Jorda M; Gomez-Fernandez C; Velez Torres JM
    Cancer Cytopathol; 2023 Sep; 131(9):586-595. PubMed ID: 37358081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PREDICTIVE VALUE OF SOMATIC MUTATIONS FOR THE DEVELOPMENT OF MALIGNANCY IN THYROID NODULES BY CYTOPATHOLOGY.
    Halászlaki C; Tóbiás B; Balla B; Kósa JP; Horányi J; Bölöny E; Nagy Z; Speer G; Járay B; Székely E; Istók R; Székely T; Putz Z; Dank M; Lakatos P; Takács I
    Endocr Pract; 2016 Sep; 22(9):1081-7. PubMed ID: 27214302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology.
    Yaprak Bayrak B; Eruyar AT
    BMC Endocr Disord; 2020 Apr; 20(1):48. PubMed ID: 32293401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Significance of RAS-Like Mutations and MicroRNA Profiling in Predicting Malignancy in Thyroid Biopsy Specimens.
    Cipriani NA; Johnson DN; Sarne DH; Angelos P; Reeves W; Antic T
    Endocr Pathol; 2022 Dec; 33(4):446-456. PubMed ID: 36227454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of a multigene testing for preoperative evaluation of indeterminate thyroid nodules: A prospective blinded single center study in China.
    Song Y; Xu G; Ma T; Zhu Y; Yu H; Yu W; Wei W; Wang T; Zhang B
    Cancer Med; 2020 Nov; 9(22):8397-8405. PubMed ID: 32976686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
    Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV
    Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868
    [No Abstract]   [Full Text] [Related]  

  • 37. Preoperative Role of RAS or BRAF K601E in the Guidance of Surgery for Indeterminate Thyroid Nodules.
    Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
    World J Surg; 2020 Jul; 44(7):2264-2271. PubMed ID: 32227276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [On-site fine-needle aspiration cytology of thyroid nodules. Quality assurance of the Bethesda System for Reporting Thyroid Cytopathology (2008)].
    Bak M; Péter I; Nyári T; Simon P; Újlaky M; Boér A; Kásler M
    Orv Hetil; 2015 Oct; 156(41):1661-6. PubMed ID: 26551169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of driver mutations in plasma cell-free nucleic acids in differentiated thyroid neoplasm.
    Dutta S; Tarafdar S; Mukhopadhyay P; Bhattacharyya NP; Ghosh S
    Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36744987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. American College of Radiology thyroid imaging report and data system combined with K-RAS mutation improves the management of cytologically indeterminate thyroid nodules.
    Wu H; Zhang B; Cai G; Li J; Gu X
    PLoS One; 2019; 14(7):e0219383. PubMed ID: 31295281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.